

DAFTAR PUSTAKA

Adsule, S.M., Baig, M.S., Gade, P.R. and Khandelwal, P.N., 2009. A comparative evaluation of safety and efficacy of rosuvastatin, simvastatin, and atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia. *International journal of diabetes in developing countries*, 29(2), p.74. Chahil, T. J., & Ginsberg, H. N., 2006. *Diabetic Dyslipidemia. Endocrinology and Metabolism Clinics of North America*, 35(3), 491–510. doi:10.1016/j.ecl.2006.06.002

American Diabetes Association, 2010. Diagnosis and classification of diabetes mellitus. *Diabetes care*, 33(Supplement 1), pp.S62-S69.

American Diabetes Association, 2018. 9. Cardiovascular disease and risk management: standards of medical care in diabetes—2018. *Diabetes care*, 41(Supplement 1), pp.S86-S104.

Arca, M., Pigna, G. and Favoccia, C., 2012. Mechanisms of diabetic dyslipidemia: relevance for atherogenesis. *Current vascular pharmacology*, 10(6), pp.684-686.

Casqueiro, J., Casqueiro, J. and Alves, C., 2012. Infections in patients with diabetes mellitus: A review of pathogenesis. *Indian journal of endocrinology and metabolism*, 16(Suppl1), p.S27.

Cehade, J.M., Gladysz, M. and Mooradian, A.D., 2013. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. *Drugs*, 73(4), pp.327-339.

Choi, S.H. and Ginsberg, H.N., 2011. Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. *Trends in Endocrinology & Metabolism*, 22(9), pp.353-363.

Cholesterol Treatment Trialists' (CTT) Collaborators, 2008. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet*, 371, pp.117-25.

Cholesterol Treatment Trialists' (CTT) Collaborators, 2010. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. *The Lancet*, 376(9753), pp.1670-1681.

Colhoun, H.M., Betteridge, D.J., Durrington, P.N., Hitman, G.A., Neil, H.A.W., Livingstone, S.J., Thomason, M.J., Mackness, M.I., Charlton-Menys, V., Fuller, J.H. and Cards Investigators, 2004. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *The Lancet*, 364(9435), pp.685-696.

Dalal, J.J., Padmanabhan, T.N.C., Jain, P., Patil, S., Vasawala, H. and Gulati, A., 2012. LIPITENSION: Interplay between dyslipidemia and hypertension. *Indian journal of endocrinology and metabolism*, 16(2), p.240.

Dokken, B.B., 2008. The pathophysiology of cardiovascular disease and diabetes: beyond blood pressure and lipids. *Diabetes Spectrum*, 21(3), pp.160-165.

Duvillard, L., Florentin, E., Lizard, G., Petit, J.M., Galland, F., Monier, S., Gambert, P. and Vergès, B., 2003. Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy. *Diabetes Care*, 26(5), pp.1540-1544.

Farmer, J.A., 2008. Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials. *Current diabetes reports*, 8(1), pp.71-77.

Garg, A. and Grundy, S.M., 1997. Diabetic dyslipidemia and its therapy. *Diabetes Reviews*, 5(4), pp.425-433.

Goldberg, I.J., 2001. Diabetic dyslipidemia: causes and consequences. *The Journal of Clinical Endocrinology & Metabolism*, 86(3), pp.965-971.

Goldberg, R.B., Mellies, M.J., Sacks, F.M., Moyé, L.A., Howard, B.V., Howard, W.J., Davis, B.R., Cole, T.G., Pfeffer, M.A. and Braunwald, E., 1998. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. *Circulation*, 98(23), pp.2513-2519.

Haffner, S.M., Alexander, C.M., Cook, T.J., Boccuzzi, S.J., Musliner, T.A., Pedersen, T.R., Kjekshus, J. and Pyörälä, K., 1999. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. *Archives of Internal Medicine*, 159(22), pp.2661-2667.

Heart Protection Study Collaborative Group, 2003. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *The Lancet*, 361(9374), pp.2005-2016.

Heart Protection Study Collaborative Group, 2011. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial. *The Lancet*, 378(9808), pp.2013-2020.

Herman, W.H., Alexander, C.M., Cook, J.R., Boccuzzi, S.J., Musliner, T.A., Pedersen, T.R., Kjekshus, J. and Pyörälä, K., 1999. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. *Diabetes Care*, 22(11), pp.1771-1778.

Hirano, T., 2018. Pathophysiology of diabetic dyslipidemia. *Journal of atherosclerosis and thrombosis*, p.RV17023.

Jaiswal, M., Schinske, A. and Pop-Busui, R., 2014. Lipids and lipid management in diabetes. *Best Practice & Research Clinical Endocrinology & Metabolism*, 28(3), pp.325-338.

Josten, S., 2018. Profil Lipid Penderita Diabetes Mellitus Tipe 2 P. *Indonesian Journal of Clinical Pathology and Medical Laboratory*, 13(1), pp.20-22.

LaRosa, J.C., Grundy, S.M., Waters, D.D., Shear, C., Barter, P., Fruchart, J.C., Gotto, A.M., Greten, H., Kastelein, J.J., Shepherd, J. and Wenger, N.K., 2005. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *New England journal of medicine*, 352(14), pp.1425-1435.

Lemeshow, S., Hosmer, D.W., Klar, J., Lwanga, S.K. and World Health Organization, 1990. *Adequacy of sample size in health studies*. Chichester: Wiley. pp.12-13.

Liao, J. K. (2007). *Safety and Efficacy of Statins in Asians*. *The American Journal of Cardiology*, 99(3), 410–414. doi:10.1016/j.amjcard.2006.08.051

Murphy, S.A., Cannon, C.P., Wiviott, S.D., McCabe, C.H. and Braunwald, E., 2009. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes: from the PROVE IT–TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22) trial. *Journal of the American College of Cardiology*, 54(25), pp.2358-2362.

National Institutes of Health, 2001. ATP III guidelines at-a-glance quick desk reference. *NIH publication*, pp.01-3305.

Panduan Pengelolaan Dislipidemia Perhimpunan Endokrinologi Indonesia di Indonesia Tahun 2015. 2015 : Perhimpunan Endokrinologi Indonesia (Perkeni)

Panduan Tatalaksana Dislipidemia Perhimpunan Dokter Spesialis Kardiovaskular Indonesia Tahun 2017. 2017 : Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (Perki)

Papadakis, J.A., Millionis, H.J., Press, M. and Mikhailidis, D.P., 2001. Treating dyslipidaemia in non-insulin-dependent diabetes mellitus—a special reference to statins. *Journal of diabetes and its complications*, 15(4), pp.211-226.

Parris, E. S., Lawrence, D. B., Mohn, L. A., & Long, L. B. (2005). *Adherence to Statin Therapy and LDL Cholesterol Goal Attainment by Patients With Diabetes and Dyslipidemia. Diabetes Care*, 28(3), 595–599. doi:10.2337/diacare.28.3.595

Pastromas, S., Terzi, A.B., Tousoulis, D. and Koulouris, S., 2008. Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus. *International journal of cardiology*, 126(1), pp.3-12.

Pearson, T. A., Laurora, I., Chu, H., & Kafonek, S. (2000). *The Lipid Treatment Assessment Project (L-TAP). Archives of Internal Medicine*, 160(4), 459. doi:10.1001/archinte.160.4.459

Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia Tahun 2019. 2020. Indonesia : Perkumpulan Endokrinologi Indonesia (Perkeni).

Infodatin : Siutasi dan Analisis Diabetes. 2014. Indonesia : Pusat Data dan Informasi Kementerian Kesehatan Republik Indonesia (Pusdatin).

Regensteiner, J.G. and Hiatt, W.R., 2002. Current medical therapies for patients with peripheral arterial disease: a critical review. *The American journal of medicine*, 112(1), pp.49-57.

Save, V., Patil, N., Moulik, N. and Rajadhyaksha, G., 2006. Effect of atorvastatin on type 2 diabetic dyslipidemia. *Journal of cardiovascular pharmacology and therapeutics*, 11(4), pp.262-270.

Schofield, J.D., Liu, Y., Rao-Balakrishna, P., Malik, R.A. and Soran, H., 2016. Diabetes dyslipidemia. *Diabetes Therapy*, 7(2), pp.203-219.

Shapiro, M.D. and Fazio, S., 2017. Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease. *F1000Research*, 6.

Stancu, C. and Sima, A., 2001. Statins: mechanism of action and effects. *Journal of cellular and molecular medicine*, 5(4), pp.378-387.

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, 2002. *Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)*. *JAMA: The Journal of the American Medical Association*, 288(23), 2998–3007. doi:10.1001/jama.288.23.2998

Vergès, B., 2015. Pathophysiology of diabetic dyslipidaemia: where are we?. *Diabetologia*, 58(5), pp.886-899.

Wägner, A.M., Jorba, O., Bonet, R., Ordóñez-Llanos, J. and Pérez, A., 2003. Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. *The Journal of Clinical Endocrinology & Metabolism*, 88(7), pp.3212-3217.

Wu, L., & Parhofer, K. G, 2014. *Diabetic dyslipidemia*. *Metabolism*, 63(12), 1469–1479. doi:10.1016/j.metabol.2014.08.010

Yan, A.T., Yan, R.T., Tan, M., Hackam, D.G., Leblanc, K.L., Kertland, H., Tsang, J.L., Jaffer, S., Kates, M.L., Leiter, L.A. and Fitchett, D.H., 2006.

Contemporary management of dyslipidemia in high-risk patients: targets still not met. *The American journal of medicine*, 119(8), pp.676-683.

Yudin, Z.M., Yaacob, L.H., Hassan, N.B., Ismail, S.B., Draman, N.A.N.I. and Yusoff, S.S.M., 2017. Achievement of LDL cholesterol goal and adherence to statin by diabetes patients in Kelantan. *The Malaysian journal of medical sciences: MJMS*, 24(3), p.44.

Zhou, Q. and Liao, J.K., 2010. Pleiotropic effects of statins. *Circulation Journal*, 74(5),pp.818-82